Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06766058 | Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. | recruiting | N/A | 300 | National Cancer Centre, SingaporeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06855654 | Promoting Resilience in Women With Breast Cancer (PRISM -MBC)(PRISM-MBC) | recruiting | N/A | 120 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 15, 2026 |
| clinicaltrials |
| NCT06897488 | EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | recruiting | Phase 2 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07038785 | Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs(PINK) | recruiting | — | 1,204 | SpotitEarlyINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07357298 | Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer | recruiting | Phase 3 | 156 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06023576 | A Study of Blood Pressure Control During Cancer Treatment | recruiting | Phase 2 | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06637306 | Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | recruiting | Early Phase 1 | 15 | Rima PatelOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07053085 | A Study of Surgery and Radiotherapy in People With Breast Cancer | recruiting | Phase 2 | 178 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07395336 | Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)(COMBINE-01) | recruiting | Phase 2 | 26 | European Institute of OncologyOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07587957 | Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors | recruiting | N/A | 40 | Florida Atlantic UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02250352 | Core Biopsies for Establishing a Breast Tumor Tissue Repository | recruiting | — | 400 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05831878 | RC48-ADC in HER2-low Advanced Breast Cancer | recruiting | N/A | 36 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06909604 | Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy(FHERAD) | recruiting | N/A | 50 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06931769 | TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer(TAO) | recruiting | — | 100 | The Netherlands Cancer InstituteOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07095569 | Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain | recruiting | N/A | 60 | National Cancer Institute, EgyptOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07283692 | Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | recruiting | Phase 2 | 46 | RenJi HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07582887 | Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response | recruiting | — | 70 | Fundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583485 | GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting(THERapy) | recruiting | — | 300 | Fondazione OncotechOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05317221 | Developing Breast (Cancer) Organoids | recruiting | — | 60 | Maastricht Radiation OncologyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT05598879 | Global Cardio Oncology Registry(G-COR) | recruiting | — | 5,000 | The Cleveland ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05634889 | The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.(T-REX) | recruiting | N/A | 1,350 | Region SkaneOTHER | 3 | May 11, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06523894 | Ablative SBRT in Elderly BC Patients(EASE) | recruiting | N/A | 36 | University Hospital, GenevaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06636370 | Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial(DENSE-2) | recruiting | N/A | 36,000 | C.H. van GilsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07441733 | Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients(INFLUENCE II) | recruiting | N/A | 40 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05740787 | Chemotherapy Induced Cognitive Impairment(CONCERT) | recruiting | — | 50 | University of AberdeenOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06081959 | Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06279364 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 524 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07071337 | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | recruiting | Phase 3 | 430 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07258108 | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07436312 | Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer(U-TRANS) | recruiting | N/A | 170 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07574671 | Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer | recruiting | N/A | 12 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07574749 | Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy | recruiting | — | 1,500 | Fudan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT01042548 | Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum | recruiting | — | 300 | University of PittsburghOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02743858 | Lymphedema Surveillance Study | recruiting | — | 1,250 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04771871 | MicroRNA Profiles in Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 42 | University College Hospital, IbadanOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 484 | Canadian Cancer Trials GroupNETWORK | 1 | May 7, 2026 | clinicaltrials |
| NCT05972343 | COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07572370 | Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer(De-Escalation) | recruiting | — | 560 | Royal College of Surgeons, IrelandOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03990896 | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05406232 | Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | recruiting | — | 36 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials